Immunimedics Granted Patent
January 08, 2010 at 12:54 PM EST
Immunomedics Inc. (Nasdaq: IMMU) received a patent for its proprietary autoimmune disease treatment epratuzumab. The stock price surged $1.22 to $4.49.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.